Memantine (Axura)
Substance developed by the Merz research organization used to treat dementia and Alzheimer's Disease.
memantine.com - Product Characteristics
Name of the medicinal product. Qualitative and quantitative composition ... New Memantine Literature. Brief Profile. Product characteristics. Mode of Action ...
Buy Memantine (Ebixa) - Optimal Health Products
Buy Memantine (Ebixa) online - 50 x 10 mg tablets Memantine - brand name Ebixa is a novel new drug that is showing a lot of promise in the battle against Alzheimer's ...
Memantine, China Memantine products- China Memantine Manufacturer, supplier
China Memantine, China Memantine products, provided by China manufacturer & supplier ... Home " Product Directory " Health & Medicine " Pharmaceutical ...
Memantine hydrochloride Manufacturer exporting direct from China
Product information for Memantine hydrochloride from Zhangjiagang Elecars & Gowchem I/E Co., Ltd.. Source what you need here!
Memantine Products
Memantine Products Information ... Memantine Products. Search: (e.g. Acne, Diabetes, Acupuncture, Homeopathy, etc.) Directory: ...
Memantine Tablets (Ebixa) 50x10mg Tablets Biogenesis AntiAging
Memantine Tablets (Ebixa) 50x10mg Tablets - tackles premature aging of the brain Biogenesis Antiaging is a retail ... This product can NOT be shipped to South ...
Canada Pharmacy - Namenda MemantineEbixaAxura product information, side ...
Chemical Name: MEMANTINE me-MAN-teen<P>Namenda is used to treat the symptoms of ... This product goes under several different names: Namenda in the USA, Axura, ...
Memantine (Auxura ® -Ebixa ® ) - HEP
Health Enhancement Products - Cost effective cognitive enhancement & life ... Memantine.com Product information, tests and studies. Memantine Order Memantine Axura ® ...
PATIENT INSTRUCTIONS FOR NAMENDA
coated tablets containing 5 mg and 10 mg of memantine hydrochloride. ... instruction sheet that is enclosed with the product. Patients/caregivers ...
|
Institute for rational pharmacotherapy Ebixa (memantine)Ebixa is a new medicinal product for the treatment of patients with moderately severe to severe Alzheimer’s disease. There are no other medicinal products currently available on the market for the treatment of this group of patients. Its efficacy – in halting the progress of the disease – has been demonstrated compared to placebo in studies with durations of up to 28 weeks. One open, uncontrolled study suggests that this effect may persevere for an additional six months.The largest of these studies had a duration of six months, and its population comprised 252 patients with moderately severe to severe Alzheimer’s disease randomised to memantine 20 mg/day or placebo. The primary efficacy parameters comprised an assessment of both global and functional domain status.